Acetyl-CoA the Key Factor for Survival or Death of Cholinergic Neurons in Course of Neurodegenerative Diseases

Andrzej Szutowicz · Hanna Bielarczyk · Agnieszka Jankowska-Kulawy · Tadeusz Pawełczyk · Anna Ronowska

Received: 23 March 2013 / Revised: 19 April 2013 / Accepted: 22 April 2013 / Published online: 16 May 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract Glucose-derived pyruvate is a principal source of acetyl-CoA in all brain cells, through pyruvate dehydrogenase complex (PDHC) reaction. Cholinergic neurons like neurons of other transmitter systems and glial cells, utilize acetyl-CoA for energy production in mitochondria and diverse synthetic pathways in their extramitochondrial compartments. However, cholinergic neurons require additional amounts of acetyl-CoA for acetylcholine synthesis in their cytoplasmic compartment to maintain their transmitter functions. Characteristic feature of several neurodegenerating diseases including Alzheimer’s disease and thiamine diphosphate deficiency encephalopathy is the decrease of PDHC activity correlating with cholinergic deficits and losses of cognitive functions. Such conditions generate acetyl-CoA deficits that are deeper in cholinergic neurons than in noncholinergic neuronal and glial cells, due to its additional consumption in the transmitter synthesis. Therefore, any neuropathologic conditions are likely to be more harmful for the cholinergic neurons than for non-cholinergic ones. For this reason attempts preserving proper supply of acetyl-CoA in the diseased brain, should attenuate high susceptibility of cholinergic neurons to diverse neurodegenerative conditions. This review describes how common neurodegenerative signals could induce deficits in cholinergic neurotransmission through suppression of acetyl-CoA metabolism in the cholinergic neurons.

Keywords Acetyl-CoA · Alzheimer’s disease · Cholinergic neurons · Neurotoxins · Pyruvate dehydrogenase · Thiamine deficiency

General Outline of Brain Energy Metabolism

Brain constitutes for 2 % of human body mass but under resting conditions it utilizes 20 % of whole body oxygen and glucose. Glucose is transported across the blood brain barrier through insulin independent, low-affinity high-capacity, glucose down regulated Glut 1 transporter. Due to the high rate of glucose utilization by brain cells its concentration in CSF is equal to two/third of its level in general circulation. Glucose is an almost exclusive energy substrate in the brain that through glycolytic pathway yields pyruvate, a key precursor of acetyl-CoA, which feeds TCA cycle. The latter is synthesized almost exclusively by pyruvate dehydrogenase complex (pyruvate: lipoate oxidoreductase acceptor acetylating, PDHC) that activities in whole brain, as well as in isolated brain mitochondria are 4–10 times higher than in respective fractions of non excitable tissues. The highest activity of PDHC was found in the hippocampus and the lowest one (60 % lower) in the medulla oblongata [1, 2]. These PDHC patterns did not correlate with differential regional distribution of ChAT activities [2, 3]. It might result form the fact that cholinergic neurons form small about 1 % fractions of entire brain cell population. Therefore, particular interactions between energy and cholinergic metabolism ought to be investigated using models containing greater density of cholinergic neurons.

A. Szutowicz · H. Bielarczyk · A. Jankowska-Kulawy · A. Ronowska
Department of Laboratory Medicine, Medical University of Gdańsk, Ul. Dębinki 7, 80-211 Gdańsk, Poland
e-mail: aszut@gumed.edu.pl

T. Pawełczyk
Department of Molecular Medicine, Medical University of Gdańsk, Gdańsk, Poland
Neurons that constitute about 10%, of brain cells consume 70% of glucose and oxygen supplied to this organ. That is due to the fact that neurons, possess high density/high glucose affinity Glut 3 transporters and their in situ, rates of metabolic fluxes of high-energy intermediates that are at least 20 times faster than in glial cells (Fig. 1) [4]. Brain may also utilize acetoacetate/β-hydroxybutyrate as a complementary source of acetyl-CoA [5, 6]. In physiological conditions levels of these ketoacids in extracellular fluids are well below 0.05 mmol/L. However, under pathologic conditions, such as diabetes, their extracellular concentrations may reach levels as high as 5 mmol/L. At such concentrations, ketoacids enter the brain through MCTs competing effectively with lactate (Fig. 1). Under in vitro conditions, these ketoacids were capable in combination with Ca and other metals alters multiple transport entities in the plasma and mitochondrial membranes and directly inhibits PDHC and aconitate. The prolonged depolarization and energy deficits increase nonquantal ACh release and inhibit its quantal Ca-dependent release. These conditions limit direct or ACL-dependent transport acetyl-CoA from mitochondria to the site of ACh synthesis in the synaptosomal compartment. The decrease of acetyl-CoA in the synaptosomal causes instant inhibition of ChAT, yielding depression of ACh pool and rates of its quantal release. Prolonged decrease of cytoplasmic [acetyl-CoA] results in adaptive suppression of ChAT expression aggravating deficits of cholinergic neurotransmission. Part of acetyl-CoA pool is utilized for intramitochondrial NAA synthesis, which is subsequently released out of the neuron. Decrease of mitochondrial acetyl-CoA results in energy deficits, and correlates with death rate of cholinergic neurons. Red arrows activation, blue arrows inhibition, green letters enzymes, black boxes neurotoxic agents (Color figure online).

Neurons that constitute about 10%, of brain cells consume 70% of glucose and oxygen supplied to this organ. That is due to the fact that neurons, possess high density/high glucose affinity Glut 3 transporters and their in situ, rates of metabolic fluxes of high-energy intermediates that are at least 20 times faster than in glial cells (Fig. 1) [4]. Brain may also utilize acetoacetate/β-hydroxybutyrate as a complementary source of acetyl-CoA [5, 6]. In physiological conditions levels of these ketoacids in extracellular fluids are well below 0.05 mmol/L. However, under pathologic conditions, such as diabetes, their extracellular concentrations may reach levels as high as 5 mmol/L. At such concentrations, ketoacids enter the brain through MCTs competing effectively with lactate (Fig. 1). Under in vitro conditions, these ketoacids were capable maintaining normal levels of ATP and phosphocreatine in different brain preparations. Moreover, in diabetic-ketotic rat brain ketoacids along with glucose or pyruvate caused marked rises acetyl-CoA, ACh synthesis and release from isolated nerve terminals [7].

Under in vitro conditions, neuronal cells utilize lactate/pyruvate as preferred energy substrates. The increase of lactate in circulation during exercise or pathologic hypoxia may cause several fold increase of its transport through the BBB. Inside the cells lactate remains in equilibrium with pyruvate due to very high activity of lactic dehydrogenase. Therefore, the net rate of its flux to pyruvate depends on utilization rate of the latter in PDHC and pyruvate carboxylase reactions. Pyruvate through PDHC reaction is almost exclusive source of acetyl-CoA in neurons and
other types of brain cells (Fig. 1). However, anaplerotic reaction of pyruvate carboxylation to oxaloacetate by pyruvate carboxylase occurs mainly in astrocytes [8]. Therefore, oxaloacetate has to be transported into the neurons through indirect oxaloacetate-aspartate and glutamine-glutamate shunts. Both metabolites are required by citrate synthase to feed TCA cycle.

Also astrocytes produce large amounts of lactate. Fraction of this metabolite is taken up and utilized by the neurons thanks to high expression of MCT in the neuronal plasma membranes, and PDHC activity in their mitochondria [9]. Therefore, the astrocyte-derived lactate is postulated to be an important precursor of acetyl-CoA and oxaloacetate-substrates for condensation reaction and energy production in neurons. Results of in vitro experiments on brain slices, synaptosomes and cultured neuronal cells demonstrate that lactate/pyruvate with L-malate are better energy substrates and precursors of acetyl moiety for ACh synthesis than glucose [10].

On the contrary, under in vivo conditions blood lactate, even in high concentrations, could not fully replace the glucose, despite of robust expression of MCT on the blood brain barrier. Only during the suckling period brain is capable to extract lactate from circulation [11]. The source of discrepancies between in vivo and in vitro experiments remains unknown.
Neurons have no capacity for acetate utilization. However, they synthesize large amounts of N-acetyl-N-aspartate (NAA) in aspartate-CoA transferase (acetyl-CoA:-aspartate N-acetyltransferase, EC 2.3.1.17) reaction located in their mitochondria. Neurons contain 98.7% fraction of overall brain pool of this metabolite (Fig. 1). Its intraneuronal concentration reaches levels 20 mmol/L [12]. NAA is transported to oligodendrocytes, where it may be hydrolysed to acetate by aspartoylase (aminohydrolase II, EC 3.5.1.15) and converted back to acetyl-CoA by acetyl-CoA synthetase (acetate:CoA ligase AMP, EC 6.2.1.1).

Overall NAA concentration in the brain is in the range of 10 mmol/kg. Therefore, its signal in the brain can be easily detected by PET and used as a marker of viability of brain neurons. The levels of NAA were found to be decreased in the specific regions of cerebral cortex in various brain pathologies including: Alzheimer’s, Parkinson’s diseases as well as Wernicke, dialysis and aluminum encephalopathies [12]. In each of these pathologies the PDHC activity and parameters of energy metabolism were found to be decreased. Experiments on animal and cellular models of these encephalopathies demonstrated inhibition of PDHC that correlated with suppression of acetyl-CoA levels in the mitochondrial compartment and the rate of cell death (Figs. 1, 2) [1, 6, 13–15]. It might directly decrease the rate of NAA synthesis in the aspartate acetyltransferase reaction. However, no direct correlation studies are available.

Oral administration of large doses of glyceride triacetate was reported to cause marked increases of acetyl-CoA and phosphocreatine levels in the rat brain [16]. This rise was linked with attenuation LPS-induced inflammatory reactions in microglia and improvement of energy metabolism in glial cells [16, 17].

Total number of astrocytic, microglial and oligodendroglial cells in the brain is 10 times greater than that of the neurons, but their oxidative metabolism utilizes only 30% of the brain glucose. They display about 4 times lower activities of PDHC, ketoglutarate dehydrogenase (2-oxoglutarate:lipate oxidoreductase acceptor acylating, EC 1.2.4.2., KDHC) and other enzymes of oxidative metabolism than neurons [18, 19]. High level of phosphorylation of E1 subunit of PDHC in astrocytes, could also inhibit pyruvate consumption in this compartment [20]. On the contrary, in astrocytes rates of glucose and lactate uptake are 2–4 times faster than in isolated neurons. Therefore, astrocytes may release both lactate and glucose to support neuronal energy metabolism [21, 22]. Accordingly, oxidative metabolism in neurons, but not in astroglia, was strongly activated by pyruvate and lactate. It gives rise to the hypothesis that under hypoxic/hypoglycemic conditions lactate may replace glucose as a principal energy substrate [21, 23].

Astrocytes also avidly take up glutamate, released from glutamatergic terminals, through EAAT1-2 transporters and convert it to L-glutamine in Pi-activated glutamine synthetase reaction [24]. Thereby, they protect postsynaptic neurons against excitotoxic injury, by excess of extracellular L-glutamate. In addition, astrocytes contain high activities of pyruvate carboxylase yielding production large amounts of oxaloacetate [8]. They supply these metabolites to the neurons in form of glutamine and aspartate, through glutamine-glutamate and aspartate shuttles, respectively [8]. Most of compartmentalization studies were performed on isolated primary neuronal or glial cell cultures, to deal with possibly homogenous cellular populations [24]. One should, however keep in mind that these cultures are still heterogeneous. For instance, primary neuronal cultures consist of neurons of different transmitter systems with dominating fraction of glutamatergic ones.

However, activities of PDHC in different brain regions displayed no correlations with distribution specific markers of cholinergic pericarya and/or terminals [2, 3, 25]. Also, differentiation of SN56 cholinergic cells was accompanied by the decrease but not increase of PDHC activity [26, 27]. It indicates that rate of acetyl-CoA synthesis by PDHC in cholinergic neurons is not positively linked with expression their transmitter phenotype (Fig. 1). On the other hand, during postnatal development the increase of ChAT activity in cerebrum was accompanied by respective elevations in PDHC levels, what might be compatible with maturation-induced activation all transmitter systems [3, 28, 29].

Age Dependent Modifications

Brain maturation stimulates glucose uptake, glycolysis and oxidative pathways due to increased expression of respective genes and enzyme levels. These alterations display temporal correlations with maturation-dependent elevations in brain cholinergic and glutamatergic transmitter metabolism, both requiring an adequate provision of acetyl-CoA by PDHC and its flux through TCA [28, 30, 31]. On the other hand, physiologic brain aging is characterized by continuous, although relatively small, decline of structural and metabolic markers of cholinergic neurons and their key physiological neurotransmitter functions. Also, no alterations in activities of key enzymes of oxidative metabolism including PDHC, KDHC, aconitase and other enzymes of TCA cycle and respiratory chain were found [25]. However, in these conditions deficits in several antioxidative species such as glutathione, carnotine and lipote along with excessive glutamatergic signaling, and free radical production appeared [32–34]. That, made aged brains increasingly vulnerable to common pathologic conditions such as hypoxia, hypoglycemia, excitotoxic...
stimulation, amyloid-β accumulation, Zn, Fe, Al excess and thiamine (TD) or other vitamin deficiencies (Fig. 1).
All these pathologic signals strongly inhibited PDHC, KDHC, aconitase [citrate (isocitrate)hydrolase, EC 4.2.1.3.] and other key enzymes of acetyl-CoA and energy metabolism (Fig. 1) [14, 27, 35–38]. It might cause fast decay of cholinergic neurons located in the septal nuclei (Fig. 2a, b), thereby aggravating age-dependent physiologic limitations of memory and cognitive functions [39].
In addition, other studies on 24 months rats revealed marked 40 % decrease of PDHC activity, with concomitant increases in expression and activity of pyruvate dehydrogenase kinase (ATP:[pyruvate dehydrogenase (acytelytransfering)] phosphotransferase, EC 2.7.11.2.), yielding hiperphosphorylation of PDHC-E1 subunit. That, could be responsible for decreased levels of ATP and increased accumulation of lactate in senescent brains [40].

Key Role of Acetyl-CoA

Acetyl-CoA is a key energy precursor-intermediate in all cells of our organism. In the brain it is almost exclusively synthesized in the mitochondria in PDHC reaction providing 97 % of energy (Fig. 1). Brain does not utilize fatty acids as a source of acetyl-CoA. However, during systemic ketosis it may utilize β-hydroxybutyrate-derived acetoacetate through acetoacet-CoA synthetase, succinyl-CoA acetyltransferase, and acetoacetyl-CoA thiolase reactions. Irrespective of the origin, acetyl-CoA is efficiently incorporated into TCA cycle through high activity citrate synthase step. Its equilibrium constants equal to 2.2 × 10^8 shifts this reaction far toward citrate formation [41]. It causes the level of acetyl-CoA in brain mitochondria being low and strongly dependent on the rate of its synthesis by PDHC (Fig. 1). Therefore, any conditions suppressing PDHC activity decrease acetyl-CoA level in the brain mitochondria. Significant correlations between PDHC activity and acetyl-CoA levels have been reported in our studies on different models of neurodegeneration (Fig. 2a, b) [6, 12, 42–44].

In last 40 years number of studies directly assessed acetyl-CoA content in different brain preparations [7, 43, 45–55]. However, majority of them did not take into account apparent differences in acetyl-CoA distribution between mitochondrial and cytoplasmic compartments in cholinergic and noncholinergic neurons as well as in glial cells. Only experiments performed either on brain nerve terminals or in clonal cholinergic neuronal SN56 cell lines assessed subcellular distribution of acetyl-CoA, so far [14, 36, 38, 45, 56]. These models enabled one to investigate acetyl-CoA shifts between mitochondrial and cytoplasmic compartment in pure cholinergic cells under different physiologic and pathogenic conditions (Figs. 1, 2).

Small fraction of mitochondrial acetyl-CoA, not used in TCA cycle, serves as a source of acetyl units for different synthetic processes taking place in cytoplasmic compartment of these neuronal cells (Fig. 1). However, in resting neurons inner mitochondrial membrane is relatively impermeable for acetyl-CoA and other acyl-CoA esters [6, 57]. Therefore, acetyl units are transported to cytoplasm indirectly, in the form of citrate, acetyl-L-carnitine, or acetate (Fig. 1) [57]. Citrate leaves mitochondria through dicarboxylate transporter to be cleaved by ATP-citrate lyase (acetyl-CoA:oxaloacetate C-acyltransferase [(pro-S)carboxymethyl-forming, ADP phosphorylating, EC 2.3.3.8, ACL) to acetyl-CoA and oxaloacetate. Studies with specific inhibitor of ACL (−) hydroxycitrate revealed that this pathway provides about 30–50 % of acetyl units in the cytoplasmic compartment of both neuronal and glial cells [44, 45, 58]. On the other hand, carnitine acetyl transferase system (acetyl-CoA:carnitine O-acyltransferase, EC 2.3.1.7) in the brain mitochondria was found to be active only in the presence of exogenous acetyl-L-carnitine (ALC) [59, 60]. Also immature brains were reported to take up and metabolize ALC from the blood more avidly than the adult ones [61].

Studies on whole brain mitochondria of mixed glial-neuronal origin have demonstrated that pathophysiologically relevant [Ca^{2+}] of 10^{-6} mol/L concentrations, evoked direct release of acetyl-CoA (Fig. 1) [14, 45, 50]. Also in synaptosomes adequate fraction of their mitochondrial acetyl-CoA was found to reach cytoplasm directly through Ca-activated, verapamil-inhibited pathway (Fig. 1) [45, 56]. In primary neurons depolarization increased cytoplasmic [Ca^{2+}], and opened reversible, high permeability transition anionic channels (PTP) through which acetyl-CoA moieties might diffuse from mitochondria to cytoplasm, down the concentration gradient [36, 62].

In addition, acetyl-CoA may leave mitochondria as NAA. [12]. Concentrations of substrates for aspartate N-acetyltransferase, aspartate and acetyl-CoA, are estimated to be about 1.0 and 0.12 mmol/L [36], whereas corresponding Km values are equal to 0.58 and 0.058 mmol/L, respectively [36, 63]. Therefore, pathologies that depress acetyl-CoA formation by PDHC in the brain are likely to decrease its NAA levels. Indeed, the loss of NAA was observed in brain PET scans of AD and PD patients [13, 64]. Neurons cannot utilize NAA as a source of acetate as they contain no aspartoylehydrolase in their cytoplasm. Therefore, NAA may serve as an acetyl moiety donor after its release to extracellular space followed by its uptake by oligodendroglia. The metabolic flux of acetyl units through this pathway was estimated to be equal to 2.5–3.0 % of rates of glucose to pyruvate and 1.2 % pyruvate to acetyl-CoA conversion rates, respectively [12, 36].
These data indicate that there is an intra and intercellular compartmentalization of acetyl-CoA in the brain. Acetyl-CoA in each cellular compartment of the brain forms two metabolically linked but functionally independent pools (Fig. 1). Brain mitochondria are the primary compartment for acetyl-CoA synthesis by the PDHC. Over 90% of acetyl-CoA is subsequently utilized for energy production. Thus, availability of this metabolite in mitochondria may be a key factor determining viability of neuronal and other cell types in brain (Figs. 1, 2b) [27]. Concentration of acetyl-CoA in the mitochondrial matrix is 5–7 times higher than in cytoplasm and might determine rates of its transport to latter compartment [36]. On the other hand, the influence of cytoplasmic acetyl-CoA itself on velocity of different synthetic pathways seems to be independent of the mitochondrial pool (Fig. 2e) [38, 65].

Age-Dependent Alterations of Brain Acetylcholine Metabolism

Cholinergic Transmission

The cholinergic transmission is performed by specific groups of neurons, which synthesize ACh in cytoplasmic compartment, accumulate in synaptic vesicles and release it into the synaptic cleft in a quantal, Ca-dependent mode. Neurotransmitter binding with subsequent activation of postsynaptic muscarinic and nicotinic receptors is connected with cognitive functions, emotional reactions as well as short and long term memory formation in humans and animals.

ACh is synthesized by choline acetyltransferase (acetyl-CoA:choline O-acetyltransferase, EC 2.3.1.6., ChAT) from acetyl-CoA and choline in cytoplasmic compartment of cholinergic neuron axonal terminals which equilibrium constant equal to 13 favors formation of this transmitter:

\[
\text{choline} + \text{acetyl-CoA} \rightleftharpoons \text{ACh} + \text{CoA}
\]

(1)

The release of ACh creates out of equilibrium conditions in transmitter synthesizing compartment and triggers ChAT reaction. There is thought, that transmitter functions are executed by ACh synthesized in cholinergic nerve terminals and accumulated in synaptic vesicles and released in a quantal mode in response to their depolarization. The content of ACh in cholinergic neurons is maintained on quite stable level despite of marked variations in their activity [6, 66]. It indicates that ChAT activity in cholinergic neurons in situ is high enough to prevent ACh depletion during their activity. Levels of acetyl-CoA and choline in cytoplasm of cholinergic neurons were found to be much below their optimal concentrations used in assay media [6, 66]. Therefore, the rate of ACh synthesis under out of equilibrium conditions, induced by the evoked transmitter release, may be regulated by both ChAT protein level, as well as by substrates availability.

Both ChAT and VACHT are recognized specific structural markers for cholinergic neurons. Their levels depend on the expression of CHAT and VACHT genes sharing common cholinergic locus regulated by promoters, activated by CREB and retinoic acid receptors (RAR) [67]. Also nerve growth factor (NGF) was found to induce differentiation of septal cholinergic neurons through multiple signaling pathways linked with TrkA, high affinity surface receptors and suppressed through low specificity p75 receptors [27, 54, 55, 68]. Activation of these pathways leads to increased expression of ChAT, VACHT, high affinity choline transport system (CHT1) yielding morphologic maturation and activation of ACh metabolism [54, 69, 70].

Both in ageing animals and in humans decrease in cortical ACh metabolism precedes those in ChAT and VACHT expression [6, 71–73]. In rats, loses in these cholinergic markers, as well as decreased density of cholinergic neurons in the septum, and progressive cognitive deficits appeared several months later. However, in senescence-accelerated, 8th and 12th month old mice, loses in activity and mRNA for ChAT in hippocampus and cerebral cortex as well as decreases in density of septal cholinergic neurons significantly correlated with deterioration their spatial cognitive tests [74]. There are suggestions that age-linked neurodegeneration may be caused by disequilibrium between TrkA and p75NTR receptors [75].

Metabolism of Acetyl Moiety of Acetylcholine

There is little data on regulation of acetyl-CoA metabolism in brain cholinergic neurons. It results from the fact that cholinergic neurons constitute about 1 and 10% of whole brain cell and nerve terminal populations, respectively [76]. Therefore, any conclusion concerning pathologic alterations in acetyl-CoA metabolism in cholinergic neurons, are drawn with assumption, that changes of this metabolite in cholinergic and noncholinergic compartments remain the same. However, that may not be the case. For instance, clonal SN56 cholinergic cells from mouse septum, with low and high expression of the cholinergic phenotype, had higher and lower levels of acetyl-CoA in their mitochondria, respectively (Fig. 2f) (Table 1) [38, 54, 77].

Acetyl-CoA for synthesis of transmitter pool of ACh is synthesized almost exclusively inside of cholinergic neuron mitochondria by PDHC from glucose-derived pyruvate (Fig. 1). In ketotic diabetes part acetyl units for ACh synthesis may be provided by acetoacetate/β-
| Experimental model | Neurotoxin/mode of application/level | Parameter—relative effect of neurotoxin | References |
|--------------------|--------------------------------------|----------------------------------------|------------|
| 11–13 months old   | Aβ<sub>1-42</sub> brain level (nmol/kg) (%) of wild type siblings | Glucose utilization Learning | [171] |
| FVB/N mice-brain   | 0.175 CtxT 67, CtxO 64, Inf.col. 98 | 67, 64, 100 | 25, 100 |
| WT sibiling mice-brain | <0.002 | 100 | 100 |
| RN46 cell line culture | Aβ<sub>25-35</sub> added 48 h (mmol/L) | MTT reduction rate (% control) | [151] |
| CNTF-cholinergic diff. | 0.01 | 56 | |
| BDNF-serotoninergic | 0.01 | 100 | |
| SN56 cholinergic cells culture | Aβ<sub>25-35</sub> added 24 h (mmol/L) | Relative effects-% (+) increase (−) decrease | [55] |
| Nondifferentiated | 0.001 | +11 −8 −10 | −10 |
| Differentiated | 0.001 | +31 −40 −39 | −64 |
| Primary neuronal culture | Aβ<sub>25-35</sub> added 24 h (mmol/L) | Relative effects-% (+) increase (−) decrease | [152] |
| Hippocampus | 0.025 | −86 +89 | +88 |
| Cortex | 0.025 | −42 +33 | +38 |
| 17 months old brain synaptosomes | Aβ<sub>1-42</sub> brain level (mmol/kg) | Relative values (% of WT siblings) | [165] |
| Tg2576 mice | 0.008 | 60 71 106 60 | 60 |
| WT siblings | n.d. | 100 | |
| Primary neuronal culture | SNAP added 24 h (mmol/L) | Relative effects-% (+) increase (−) decrease | [135] |
| Medial septum | 0.5 | +69 | −60 |
| Brain stem | 0.5 | +21 | 0 |
| SN56 cholinergic cells culture | SNAP added 24 h (mmol/L) | Relative effects-% (+) increase (−) decrease | [137] |
| Nondifferentiated | 1.0 | +12 | 0 |
| Differentiated | 1.0 | +34 | +31 |
| SN56 cholinergic cells culture | SNP added 10 min (mmol/L) | Relative effects-% (+) increase (−) decrease | [15, 79] |
| Nondifferentiated | 1.0 | +15 +27 +34 | +1 −28 −42 −30 |
| Differentiated | 1.0 | +23 −15 +37 | n.d. −56 −50 −41 |
Table 1 continued

| Experimental model                  | Neurotoxin/mode of application/level | Parameter—relative effect of neurotoxin | References  |
|-------------------------------------|--------------------------------------|----------------------------------------|-------------|
|                                     | Cholinergic cell lines culture       | Relative effects (fold)                | [134]       |
| Medial septum-derived               | SNAP added 24 h (mmol/L)             | P-ERK2                                 | 14          |
|                                     |                                      | DNA fragmentation                       |             |
| Brain stem-derived                  | 0.1                                  | 2.1                                    |             |
|                                     | 0.1                                  | 1.2                                    | 10          |
| SN56 cholinergic cells culture      | Zn added 30 min (mmol/L)             | Relative effects-% (+) increase (-) decrease | [38]        |
| Nondifferentiated                   | 0.2                                  | +22                                    | –23         | –100         | –25         | –68         |
|                                     | Differentiated                       | 0.2                                    | +42         | –53          | –88         | –17         | –141        |
| SN56 cholinergic cell culture       | Cell clone                           | Relative values-fold of nondifferentiated wild type | [77]        |
| Nondifferentiated                   | Wild type SN56                       | ChAT                                   | 1.0         | 1.0          | 1.0         | 1.0         |
|                                     | Differentiated                       | PDHC                                   | 1.0         | 0.86         | 0.72        | 2.20        |
| Nondifferentiated                   | SN56ChAT2                            | acetyl-CoA_{mit}                       | 17.2        | 0.92         | 0.38        | 2.17        |
|                                     | Differentiated                       | acetyl-CoA_{cyt}                       | 30.9        | 0.86         | 0.27        | 2.89        |
| SN56 cholinergic cell culture       | Amprolium added 48 h. (mmol/L)       | Relative effects-% (+) increase (-) decrease | [131]       |
| Nondifferentiated                   | 2.0                                  | TDP                                    | –31         | +5           | –27         | –37         | –18         |
|                                     | Differentiated                       | TB (+)                                 | –31         | +13          | –44         | –46         | –33         |

Aβ, amyloid β peptides; ACh, acetylcholine content; ChAT, choline acetyltransferase activity; CxT CxO, temporal, occipital cortex; FVB/N mice, MTT, methyl tetrazolium salt reduction rate; PDHC, pyruvate dehydrogenase complex activity; SNAP, S-Nitroso-N-Acetyl-L-Penicillamine; SNP, sodium nitroprusside; SN56ChAT2, ChAT gene transfected septal cholinergic hybrid neuroblastoma cells SN56.B5.G4; TB(+), trypan blue retaining cells; TDP, thiamine diphosphate; Tg2576 APP695 double mutation K670N, M671L mice; WT, wild type cells or mice.
hydroxybutyrate [5, 7]. It is estimated, that only 1–3 % of acetyl-CoA pool synthesized in cholinergic neurons is utilized for ACh production. Despite of that there is a tight interdependence between pyruvate oxidation and ACh content and rate of release both in whole brain, isolated synaptosomes as well as in cultured cells [15, 35, 78, 79]. That may be due to the competition for acetyl-CoA between high velocity TCA and relatively slow rate transporting pathways (Fig. 1) (Table 1).

Among several pathways of acetyl group transfer through the mitochondrial membrane (see “Key Role of Acetyl-CoA”) only two seem to be significant sources of acetyl-CoA for ACh synthesis in the cholinergic neurons. They are: ACL pathway, providing 20–50 % of acetyl units, and the direct efflux of acetyl-CoA through Ca-dependent reversible PTP (Fig. 1) [44, 45, 50].

In addition, ACL pathway provides acetyl-CoA for acetylation of histones and different structural proteins of various mammalian cells including neurons [65]. Thereby, acetyl-CoA-dependent disturbances in protein acetylation may contribute to epigenetic pathomechanisms of Alzheimer’s and other neurodegenerative diseases [80, 81].

During postnatal development of cerebrum activity of ChAT increased several-fold, but the ACL activity remained on stably high level. On the other hand, in cerebellum containing no cholinergic elements, activity of ACL was decreased by about 70 % [3, 31]. Significant correlations have been found between ChAT and ACL activities in different regions of the brain, and in lesioned hippocampus [82]. Also, differentiation of cholinergic S-20 but not NIE-115 dopaminergic neuronal cells caused two-fold increase of ACL activity [83].

There is generally accepted that in resting cells in situ, mitochondrial inner membrane is impermeable to acetyl-CoA [45, 57]. However, depolarization-induced increase of cytoplasmic Ca²⁺ may generate reversible PTP, allowing transient direct release of acetyl-CoA from mitochondria to cytoplasm [45, 62, 84]. Studies with Ca chelators and Ca-channel antagonists indicate that up to 60–70 % of acetyl-CoA for ACh synthesis is transported out of mitochondria by the direct release [56].

ALC is thought to be another alternative source of acetyl units for brain ACh synthesis. Under in vivo conditions systemic application of ALC was found to improve energy and ACh metabolism in the brain, as well as cognitive performance of aged or pharmacologically depressed animals [60, 85, 86]. In fact, dietary supplementation of mice with ALC attenuated pentylentetrazole-induced seizures through restoration normal levels of ATP and NAA [87]. Beneficial effects of ALC supplementation might result from general improvement of energy metabolism and synthesis of structural lipids but not from specific influence on neurotransmission in cholinergic neurons [86, 88]. However, none of these reports assessed acetyl-CoA content in ALC treated brains. In turn, our data demonstrate that addition of ALC to cultured cholinergic neuroblastoma cells increased acetyl-CoA level in their cytoplasm and prevented A-β induced suppression of ACh metabolism (Fig. 2c, d) [55].

Direct interactions between acetyl-CoA and ACh metabolism were demonstrated by studies on nondifferentiated and cAMP/retinoic acid or NGF-differentiated cholinergic SN56 neuroblastoma cells (Fig. 2c, d). They revealed that differentiation-evoked elevations in their ChAT and ACh were accompanied by suppression of acetyl-CoA level in their mitochondria and its increase in the cytoplasmic compartment (Fig. 2f) [54, 55].

Early and Late Mechanisms of Energy and Acetyl-CoA-Dependent Disturbances in Cholinergic Encephalopathies

Principal clinical symptoms of AD and other cholinergic encephalopathies include progressive cognitive deficits leading to dementias, frequently combining with motor disability [89–91]. They correlate well with the degree of functional and structural loses of basal forebrain cholinergic neurons projecting axons to hippocampus and different cortical areas [92]. Another key feature of these pathologies is the suppression of energy metabolism, which correlates with losses of cholinergic markers in affected areas of brain cortex or spinal cord segments. Dysfunction of brain mitochondria is thought to be both the consequence of pathologic insults as well as a source of signals triggering neurodegeneration [93–95]. There is a hypothesis, that particular susceptibility of cholinergic neurons to degeneration results from the fact that their acetyl-CoA, synthesized in mitochondria by PDHC is used not only for energy production in TCA cycle and respiratory chain but also for ACh synthesis in the cytoplasmic compartment (Fig. 2a, b, f) [6, 27, 78, 96].

Alzheimer’s Disease

Alzheimer’s disease (AD) is the most frequent form of dementia in senescent population. Estimated number of patients suffering of this pathology reaches 25 million worldwide [97]. AD is a clinical-phenotypic presentation of various sporadic and inherited diseases. Immunohistochemical examinations of autopsied brains reveal accumulation of extracellular amyloid-β (Aβ) deposits and neurofibrillary tau protein type degeneration inside the neurons. The amyloidogenic form is Aβ1–42 containing 42 aminoacids, originates from proteolytic processing of transmembrane amyloid precursor protein (APP), by the
amyloid-β cleaving enzyme (BACE1, β-secretase). Dominating product of APP proteolysis by ADAM (α-secretases) is 26 aminoacid non-amyloidogenic peptide P3 (Aβ17–42 fragment) [98, 99].

The large fraction of sporadic AD patients is carrying double copies of APOE4 alleles [100, 101]. Moreover, these patients display significant associations with down-regulation of multiple transcripts of genes involved in oxidative phosphorylation, energy metabolism as well as with synaptic vesicles docking and fusion [101–103]. AD patients, being APOE4 carriers displayed strong correlation between suppression of KDHC, PDHC and ChAT activities in brain cortex and cognitive dysfunction rate [13, 104]. Reduced activities of PDHC and KDHC in autopsied AD brains displayed strong inverse correlations with clinical dementia rating [13, 105]. Also, glucose Glut 1 and 3 transporters density was reduced in affected brain areas, as demonstrated by in vivo PET and in post mortem cytochalasin B binding studies [106, 107].

The key biochemical and histopathologic finding in AD brains is preferential loss of cholinergic neurons located in septal nuclei, and their axonal projections to hippocampus and several areas of brain cortex. The decreases of several cholinergic markers such as ChAT, CHT1, VAChT activities and protein levels were observed post mortem in affected brain areas [71, 92, 105, 108]. The loss of cholinergic markers correlated with both suppression of energy metabolism and severity of dementia shown shortly before patient’s death [13, 92, 108]. Neuronal loss has been consistently shown in key cholinergic brain nuclei in sixty-seven studies over 20 year period [108]. On the other hand, several noncholinergic transmitter systems were not or much less suppressed by these conditions [109, 110, 111].

Several putative pathomechanisms are involved in AD encephalopathy. They include: Aβ7–42 accumulation, excitotoxicity/NO excess, mitochondrial dysfunction, hypoxia/anoxia/hypoglycaemia, oxygen radicals formation, inflammation, metals (Ca²⁺, Zn²⁺, Fe²⁺, Al³⁺) accumulation, or neurotoxin depletion, which were investigated as cytotoxic signals in AD (Fig. 2) [27, 90, 91, 93, 94, 112–118]. Also activation of microglia yielding increased release of proinflammatory interleukins may induce neurodegeneration through Wnt or p75 neurotrophin receptor-dependent signal transduction pathways [75, 119, 120]. On the other hand, anti-p75/Wnt antibodies or silencing respective genes, protected against excitotoxicity/inflammation-induced loss of cholinergic neurons [54, 121].

Most of these cytotoxic signals directly affected activities of enzymes linked with energy and acetyl-CoA metabolism in humans as well as animal and cellular models of AD [13, 27, 96, 102, 104, 118]. Therefore, the key effects of diverse neurodegenerative signals were limitations in acetyl-CoA availability and its intraneuronal distribution, yielding preferential disintegration of cholinergic neurons in AD brains (Figs. 1, 2). In fact, suppression of PDHC and mitochondrial energy deficits preceded appearance of AD pathology in the brains of transgenic 3xTg-AD mice. However, microarray studies revealed that in late-dementive phase of AD the depression of oxidative phosphorylation was accompanied by up-regulation of those genes [96]. It suggests that down-regulation of energy metabolism in the course of AD might be a protective response of surviving neurons to decreased supply of glucose and oxygen taking place in this pathology [96].

Excitotoxicity

Several common pathologies of ageing brain like general or focal hypoxia, hypoglycaemia, inflammation, or thiamine deficits, cause depolariization and Ca-overload of neuronal and non neuronal cells. Glutamatergic neurons constitute 50 % of all brain neurons and synaptic terminals [122]. Prolonged pathologic depolarization yields an excessive co-release of glutamate and Zn from brain “gluzinergic” terminals, triggering action potentials through NMDA, AMPA receptors and other voltage gated Ca channels located on postsynaptic neurons including cholinergic ones [123–125]. They cause dysfunction of postsynaptic neurons that, when aggravated, may evolve toward apoptosis or necrosis [126, 127].

Energy deficits also inhibit uptake of glutamate by adjacent astrocytes, due to the down-regulation of EAA, GLAST and GLT1 transporters and inhibition of their glutamine synthetase [128]. It increases glutamate and Zn levels within the synaptic clefts, yielding sustained depolarization of postsynaptic neurons, as well as adjacent astroglial and microglial cells [117]. The disruption of Ca²⁺ homeostasis affects enzymes linked with pathways involved in energy, neurotransmitter, and NO metabolism, which seem to be primary targets for excitotoxic signaling in the brain [37, 38, 118]. The Ca²⁺ excess in the mitochondrial compartment yields inhibition of PDHC due to activation of PDH kinase, being at least in part, the cause of acetyl-CoA deficits in subcellular compartments of cholinergic neuronal cells (Fig. 2) [27, 38, 129].

Zn Neurotoxicity

Zn co-released with glutamate from overexcited “gluzinergic” terminals may reach high, up to 0.3 and 1.0 mmol/L, concentrations in the synaptic cleft [113, 122]. Subsequently Zn is avidly taken up from the synaptic cleft by depolarized postsynaptic glial and neuronal cells including cholinergic ones, through the voltage gated, diltiazem-sensitive Ca-channels and specific Zn-transporting proteins [38, 116, 130]. Extended depolarization brings about...
overloading of postsynaptic neurons with Zn, irrespective of expression of their cholinergic phenotype. Zn accumulated in postsynaptic cholinergic neurons was found to inhibit several enzymes of energy metabolism with pathophysiologically relevant potencies including: KDHC > NADP isocitrate dehydrogenase > aconitase > PDHC [37, 38]. The inhibitory interactions of Zn with lipoate binding sites of PDHC and KDHC could be reversed by the delayed application of lipoamide or chelating agents. On the contrary, inhibition of aconitase and isocitrate dehydrogenase appeared to be irreversible [37]. Such inhibitory pattern may impede therapeutic attempts aimed to rescue energy metabolism in excitotoxicity-affected brains. Moreover, in human AD brain cortex the alternation pattern of enzymes of energy metabolism appeared to be very similar to that found in Zn-treated SN56 cholinergic cells [13, 37]. It provides a circumstantial evidence on significance of aberrations in intraneuronal distribution of Zn for the pathomechanism of AD.

The Zn-evoked inhibition of PDHC and other enzymes listed above, explains suppression of mitochondrial acetyl-CoA levels, and inhibition its metabolic flux through TCA cycle as a cause of ATP depletion and neuronal loss resulting from excitotoxic insults (Table 1; Fig. 2) [37, 38, 125, 126].

Subsequently, deficit of intramitochondrial acetyl-CoA would inhibit transfer of acetyl units to cytoplasm through different pathways (Fig. 1). Shortage of acetyl-CoA, in cytoplasm of cholinergic neurons, may decrease ACh level in this compartment, through ChAT equilibrium mechanism (Table 1; Fig. 2b, c, d) [66]. That in turn would reduce vesicular ACh pool available for quantal release. In this manner overload of postsynaptic cholinergic neurons with Zn could cause immediate depression of ACh synthesis, as well as its vesicular accumulation and release at early steps of neurodegeneration [46]. On the other hand, chronic excess of Zn could result in either death of some cholinergic neurons or depression ChAT activity in those surviving in these pathogenic conditions [37, 38]. Our studies revealed that differentiated cholinergic neuronal cells SN56, with high expression of the cholinergic phenotype, were more susceptible to Zn as well as other neurotoxic signals than those with low level of cholinergic metabolism (Table 1) [27, 38, 131]. This differential, phenotype-dependent susceptibility of septal cholinergic neurons to Zn-induced inputs could be directly linked with insufficient availability of acetyl-CoA in the mitochondrial compartment (Fig. 2a, b) [37, 38].

Zn itself may also increase Ca accumulation in the neurons, thereby facilitating opening PTP and release of cytochrome c, caspases and other proapoptotic proteins from mitochondria [27, 116, 132]. This excess of Ca accumulated exclusively in the cytoplasmic compartment of cholinergic neuronal cells in Zn concentration-dependent pattern [38]. It could trigger PTP formation and aberrant compartmentalization of acetyl-CoA yielding cholinergic neurons injuries [37, 118, 124, 130].

NO Excess

Gutamate-Zn evoked increase of [Ca\(^{2+}\)/[calmodulin-Ca]

in cytoplasmic compartments of postsynaptic neurons and adjacent glial cells markedly increases nNOS and eNOS activities, respectively [113, 117]. It seems however, that only increased expression of Ca-independent iNOS in the microglial/astroglial cells may contribute significantly to neurodegeneration. It has been demonstrated, that only iNOS-dependent activation may elevate the NO levels in the brain up to micromolar, pathologically relevant, concentrations [113]. In fact, bacterial lipopolysaccharides could induce several-fold increase of NO synthesis by microglia [133]. On the other hand, fraction of NO produced by nNOS/eNOS may reach levels two orders of magnitude lower, and is likely to play a physiologic roles of “volume transmitter” and guanyl cyclase activator [117].

Peroxynitrite radicals were found to react with wide range of intracellular biomolecules linked with energy metabolism, glycolytic metabolism and several regulatory and transport or neurotransmitter functions, as well as with antioxidant systems. Excess of endogenous NO exerts rapid but reversible inhibition of cytochrome c oxidase and less potent one for other proteins of respiratory chain and ATP-synthetase, as well [113, 117]. However, NO may also inhibit earlier steps of energy metabolism including: PDHC, aconitase, isocitrate NADP-dehydrogenase, as well as KDHC [35, 77, 79]. Other enzymes of TCA cycle: succinate dehydrogenase, fumarase, and malate dehydrogenase were not affected by these conditions. That could cause deficits of acetyl-CoA and ATP in neuronal cells exposed to NO/ONOO\(^-\) excess [77, 79] Cholinergic neurons with residual expression of the cholinergic phenotype appeared to be more resistant to NO neurotoxicity than those with high expression of the cholinergic phenotype, apparently due to negligible demand for acetyl-CoA to support ACh synthesis in the former (Table 1; Fig. 2f) [35, 77, 79].

Lipoic acid or ALC were found to exert positive effects on viability of NO or Zn treated cholinergic SN56 cells through preservation of high acetyl-CoA levels in their subcellular compartments (Fig. 2) [27, 35]. However, delay in cytoprotectant application markedly diminished their efficacy, apparently due to instant, irreversible inactivation of aconitase by Zn and NO excess [27, 37, 38]. ChAT appeared to be resistant to direct, acute exposition to NO-excess. However, short exposition of differentiated SN56...
cells to NO excess caused after 24 h delayed adaptive suppression of ChAT activity, apparently induced by shortages of acetyl-CoA in their mitochondrial and cytoplasmic compartments (Fig. 2b, c, d; Table 1) [15, 27, 77]. Additive effects of NO excess and Aβ were also observed (Table 1) [79]. Finally, alterations in activities of enzymes of energy metabolism in SNP-treated differentiated SN56 cells displayed pattern, similar to that reported for human AD brains [13, 35, 79]. Also cholinergic cells derived from basal forebrain were more sensitive to NO excess that those originated from brain stem, as indicated by their phospho ERK-2 and DNA fragmentation levels (Table 1) [134]. NO excess increased TUNEL reactivity, lactate dehydrogenase release and the decrease in ChAT activity in primary cholinergic neurons from medial septum, whereas those from brain stem were resistant to such conditions (Table 1) [135–137]. These data indicate that NO-derived radicals may exert differential cholinergic phenotype-specific neurotoxic effects in the brain.

**Amyloid-β Neurotoxicity**

Accumulation of fibrillar Aβ deposits in the interstitial compartments of the brain is a hallmark of AD and related amyloid encephalopathies [98, 99, 138]. The disruption of the cholinergic system and suppression of oxidative glucose metabolism were observed in brain regions with Aβ burden. Therefore, Aβ load was claimed to be the key factor triggering and supporting progress of the disease [98, 99]. However, degree of cognitive impairment correlated much better with loss of cholinergic neurons and impairment of oxidative metabolism than with Aβ burden in AD brains [13, 139]. In addition, some cholinergic encephalopathies develop without accumulation of Aβ but with impairment in brain energy metabolism [140–142]. Moreover, AD-type pathologic changes were found to affect about 80% of individuals of age 65, but only small fraction of them suffers of dementia [143]. Therefore, Aβ overload in the brain should be treated as diagnostic and staging biomarker, and not as causative factor for this pathology [144, 145]. On the other hand, one cannot exclude possibility that Aβ, after reaching some hypothetical critical level, might aggravate preceding neurotoxic signals, triggering vicious cycle of neurodegeneration. For instance, extracellular fibrillar aggregates of Aβ were found to form autonomic or NMDA-linked high conductance Ca-channels in plasma membranes triggering Ca-dependent mechanisms of cytotoxicity, including depression of energy metabolism [115].

However, effective, cytotoxic concentrations of Aβ in most in vitro experimental conditions appeared to be an order of magnitude higher than those detected in AD brains varying from 0.5 to 4.0 μmol/kg [145–147]. Aβ₁₋₄₂ in nontoxic, submicromolar concentrations inhibited PDHC and ACh synthesis/release in cultured primary septal neurons, without changing their ChAT activity [148]. This peptide also inhibited oxidative metabolism and decreased ATP contents in the PC12 cells [149]. Short time exposition to high 50 μmol/L Aβ inhibited glucose uptake and increased synthesis of free radicals in brain synaptosomes [150]. Differential, phenotype-dependent susceptibility of neurons to Aβ was reported by Olesen et al. [151]. They found, that immortalized raphe nucleus neurons, when differentiated to cholinergic phenotype with brain-derived neurotrophic factor became three times more sensitive to Aβ than those differentiated to serotoninergic phenotype with ciliary neurotrophic factor (Table 1) [151]. In addition, Aβ caused two times greater increase of free Ca in hippocampal than in cortical neurons [152]. Also injection of Aβ into rat nucleus basalis induced deficits of cholinergic neurons but increased activity of serotoninergic ones [153]. In cerebral neurons, Aβ inhibited cytochrome P450 epoxygenase, which metabolized arachidonic acid to neuroprotective epoxyeicosatrienoic acid, being inactive toward its cerebellar isof orm. Therefore, cerebral and cerebellar neurons appeared to be prone and resistant to Aβ, respectively [154]. Differentiation of cultured embryonal rat brain neurons increased their susceptibility to Aβ [155]. It was due to activation of their cyclin-dependent kinase 5, which promotes tau phosphorylation, responsible for tubulin disintegration in Aβ-exposed neurons [155]. There is also known that energy deficits in different pathologies of aging brain induce β-processing of APP [94, 156]. On the contrary, dietary high energy substrates were found to reverse neuronal hyperactivity in transgenic AD mice [157]. Studies on differentiated cholinergic SN56 cells revealed that their greater susceptibility to Aβ could be caused by lower activity of PDHC, yielding decreased availability of acetyl-CoA in their mitochondria. In addition, high basal levels of Ca both in mitochondrial and cytoplasmic compartments of differentiated cells, could facilitate detrimental effects of Aβ (Fig. 2a, e; Table 1) [27, 55, 79]. Also increased expression of p75 receptors in differentiated cells could augment their sensitivity to Aβ in the presence of NGF [27, 54, 158]. There are also indications that Aβ may aggravate neurotoxic effects of other AD-linked toxins such as Al, Zn or peroxinitrine radicals (see “Zn Neurotoxicity”, “NO Excess”) [79, 113, 118, 159]. It has been found, that Aβ, Al or NO excess exerted cumulative suppressive effects on PDHC and aconitate activities, acetyl-CoA levels, cholinergic metabolism and viability cholinergic SN56 cells in culture (Figs. 1, 2) [27, 79, 118].

On the other hand, regional accumulation of Aβ in human AD brain did not correlate with loss of respective cognitive functions [139, 160]. Accordingly, in number of patients...
with heavy Aβ load, but with normal deposition of amyloid P in the brain cortex and hippocampus, no signs of dementia have been found. On the other hand, individuals with moderate Aβ accumulation and high content of amyloid P displayed typical symptoms of AD dementia [161]. However, it does not exclude possibility that accumulated Aβ might in combination with earlier cytotoxic signals aggravate end stages of cholinergic encephalopathies.

Transgenic Animal Models of Cholinergic Degeneration

Several transgenic mice (Tg) models have been developed to study mechanisms of Aβ-dependent neurodegeneration and investigate putative therapeutic approaches to AD. All of Tgs were designed by single or multiple inserts of mutated APP, PS1 human gen(s) into mice germinal cells. If the above assumptions are correct, then Tg-AD mice should display: (1) Aβ accumulation in sensitive areas of the brain cortex in their advanced age, (2) functional and structural disruption of cholinergic neurons paralleling deficits of cognitive functions, (3) suppression of energy metabolism preceding alterations, quoted above.

1. There are significant discrepancies concerning accumulation of Aβ1–42 in brains of Tg animals. For instance, in brains of Tg2576 mice, Aβ1–42 levels reported by different authors varied from 0.13 through 0.94 µmol/kg to over 200 times higher concentrations of 30 µmol/kg of tissue (Table 1) [164–166]. What is interesting, the degree of cognitive impairment, and histochemical amyloid plaque densities were similar in all strains. Also, strikingly wide range of Aβ1–42 levels was reported for post mortem AD human brains [146, 167]. Such wide dispersion of pathologic values may, presumably result from still existing analytical problems concerning Aβ recovery, matrix effects, standardization, or specificity and avidity of used antibodies.

2. There are also significant differences between alterations in cholinergic marker levels in human AD and mice Tg brains. In human AD brains, significant decreases in ChAT activities and other cholinergic markers correlated with loss of cognitive functions (see “Alzheimer’s disease”). On the other hand, no losses of ChAT activity and VACHT levels were observed in brains of demented Tg-AD or TS65DN mice despite evident cognitive deficits [168, 169]. However, decreases in ACh content and release rates were found in Tg-AD mentally impaired mice, despite of normal ChAT activity [166, 170].

3. The inhibition of glucose uptake and pyruvate utilization in FVB mice took place, which was likely to cause deficits of acetyl-CoA for energy and ACh production (Table 1) [171]. However, no suppressions in PDHC, aconitase, ICDH-NADP and KDHC activities were found in brains of 17 months Tg 2576 mice (Table 1) [165] (Szutowicz, Schliebs unpublished). They remain in contrast with findings in human AD brains, which revealed significant decreases in activities of all enzymes listed above [13]. Data presented here indicate that in Tg mice structural integrity of cholinergic neurons is better preserved than in human AD brains. Thus, suppression of ACh metabolism and dependent cognitive functions in Tg-mice is of functional character, resulting from relatively weak inhibition of glucose and pyruvate metabolism by accumulating Aβ, which is not deadly to cholinergic neurons [14, 171, 172].

Thiamine Deficiency Encephalopathy

Animals and humans have no capacity of thiamine ring synthesis, which is the precursor of thiamine diphosphate (TDP). TDP is a cofactor of two key enzymes of energy metabolism PDHC and KDHC, providing acetyl-CoA for and limiting metabolic flux through TCA cycle, respectively. Therefore, thiamine deficits (TD) impair functions of all body tissues, yielding multi symptomatic and diverse clinical presentations of cholinergic transmission deficits. There are claims that, TD-induced inhibition of oxidative metabolism might facilitate and exacerbate amyloid plaque pathology [156, 173, 174]. In consequence, alcohol abuse, which is a most common worldwide cause of TD, should be considered as a risk factor for AD [175].

Energy and Acetyl-CoA Metabolism in Thiamine Deficient Brain

Early studies on pyrithiamine-TD rat brains reported either no change or slight decrease of acetyl-CoA levels [48, 176]. They however, addressed neither intercellular nor intracellular compartmentalization of this metabolite. So far, only few studies provided quantitative data on mitochondrial and cytoplasmic pools of acetyl-CoA in different cellular compartments in TD (Table 1, Figs. 1, 2) [36, 131].

In TD brains two major mechanisms seem to contribute to an early dysfunction and late loss of cholinergic neurons. They include: primary limitation of acetyl-CoA provision by unproductive TD-PDHC and secondary excitotoxic over-activation by glutamate-Zn released from energy-depleted
The combination of TD-evoked, direct inhibition of PDHC and KDHC and Zn-induced excitotoxicity may aggravate acetyl-CoA and energy shortages in these conditions [36, 38, 128, 177]. In such conditions reductions in intramitochondrial levels of acetyl-CoA correlated with losses of cholinergic markers and viability of cholinergic neuronal cells (Fig. 2a, b, d) [15, 27, 36–38, 131].

There is well established, that the decrease of cytoplasmic acetyl-CoA in TD SN56 cells and brain nerve terminals resulted from limited availability of this metabolite in the mitochondrial compartment (Figs. 1, 2b, c). In consequence, lower rates of ACh release in TD neurons positively correlated with decreased concentration of acetyl-CoA in their cytoplasmic compartment (Fig. 2d) [38, 131]. These findings fit to a general rule that the rate of ACh synthesis/release depends on the availability of acetyl-CoA in cytoplasmic/synaptosomal compartment of cholinergic neurons, irrespective of neurotoxic signal (Figs. 1, 2c, d) [6, 27, 118]. However, unlike for AD or other neurotoxic conditions, acute TD altered ChAT activity neither in pyrithiamine-rat brain synaptosomes nor in amiprolim-SN56 cells [38, 131, 176, 178]. These data indicate that, at least in early stages of TD, the structure of cholinergic neurons remained well preserved.

Also in this model of cholinergic pathology, neurons with high expression of the cholinergic phenotype appeared to be more susceptible to TD than those with residual cholinergic activity. There was in line with lower levels of mitochondrial acetyl-CoA in the DC (Fig. 2c; Table 1) [131]. Residual ACh metabolism in nondifferentiated cholinergic neurons was not affected by TD-induced shortages in mitochondrial and cytoplasmic acetyl-CoA (Table 1, Figs. 1, 2c, d, e) [130]. Other, in vivo observations on differential regional susceptibility of brain cholinergic neurons and energy metabolism to TD remain in accord with cell culture studies [1, 156, 179].

Choline

Choline is another precursor of ACh, which is utilized in equivalent amounts with acetyl-CoA for the transmitter synthesis. Mammalian brain has limited capacity to synthesize its own choline. Therefore, this ACh precursor has to be transported from intravascular compartment across the blood brain barrier [180, 181]. Cholinergic neuron axonal terminals possess highest density CHT1 that are specific functional proteins for their axonal terminals [182, 183]. It has been suggested, that only choline transported by CHT1 is available for ACh synthesis.

In pathological conditions, prolonged depolarization of cholinergic terminals may inhibit CHT1-dependent transport of choline from extracellular space due to collapse of membrane potential. In such conditions, choline may originate from hydrolysis of structural membrane phospholipids by phospholipase D [181]. This choline pool could supplement ACh synthesis and maintain stable transmitter level during its excessive release in course of sustained depolarization of cholinergic neurons. However, if such conditions persist the phosphatidylcholine content in membranes of cholinergic neurons would decrease, resulting in their shrinkage and death [181]. That could contribute to particular susceptibility of cholinergic neurons to neurodegenerative insults [181]. On the contrary, the increase of extracellular choline to supraphysiological concentrations increased both basal and depolarization-evoked ACh release. It indicates, that choline taken up by low affinity system could also be used for transmitter synthesis and release. These observations rationalize use of choline supplementation as a method improving ACh metabolism in age–evoked disturbances of cholinergic system in the brain [184, 185]. Unlike acetyl-CoA, choline provision for ACh synthesis is not directly dependent on the energy production. However, correction of acetyl-CoA and energy deficits in aged rats by ALC supply in drinking water elevated choline uptake as well as ACh synthesis and release [85, 182].

On the other hand, choline-deficient diets induced deficits of this precursor both in cell membranes and in the ACh synthesizing compartment [186]. Lack of membrane integrity could cause the impairment of energy production in brain mitochondria, leading to increased vulnerability of cholinergic neurons to neurodegenerative signals along with appearance of behavioral deficits [186, 187]. Such reciprocal interactions between aberrant acetyl-CoA/energy and choline metabolisms may trigger vicious cycle of early deterioration of cholinergic neurons under various neurodegenerative conditions.

Future Directions

Vast number of studies has been performed over the past three decades on the mechanisms of AD and other cholinergic encephalopathies. They employed diverse in vivo, in vitro models, and clinical studies focused mainly on disturbances in Aβ metabolism. Only small fraction of them focused on malfunctions of energy metabolism and their role in onset and progress of AD. The latter reveal decreases in PDHC and KDHC activities, which depress acetyl-CoA synthesis and utilization, in regions of brain cortex affected by this pathology [27, 118]. There is however a significant time gap between observations on acute, excitotoxic alterations in energy metabolism and late structural, irreversible changes in the neuronal network [188]. Therefore, several questions remain to be answered.
regarding time-course transition mechanisms between early, apparently reversible stages of inhibition of acetyl-CoA/energy production and delayed, irreversible phase of impairment of brain cholinergic system. To address this problem multiple time and neurotoxin dose-dependent studies on expression and posttranslational modifications in enzymes/proteins of energy metabolism and intracellular signal transduction pathways should be executed. Further studies are also necessary on reciprocal, differential acute and chronic effects of AD pathology on energy/acetyl-CoA metabolism in dominating class of glutamatergic neurons as well as astro and microglial cells to link them with acute and prolonged aberrations in their functions and integrity. They should provide a detailed map of regional and inter/intracellular compartmentalization of acetyl-CoA in the brain. This might pave the path for studies on interventions aiming to preserve acetyl group metabolism, in manner adequate to early and late stages of neurodegeneration.

Acknowledgments Work was supported by MNiSW projects 2011 046071 and NN401 0299 37 and GUMed fund St-57.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Butterworth RF, Giguere JF, Besnard AM (1985) Activities of thiamine-dependent enzymes in two experimental models of thiamine-deficiency encephalopathy: 1. The pyruvate dehydrogenase complex. Neurochem Res 10:1417–1428
2. Szutowicz A, Stepien M, Bielarczyk H, Kabata J, Lysiak W (1982) ATP citrate lyase in cholinergic nerve endings. Neurochem Res 7:799–810
3. Szutowicz A, Lysiak W (1980) Regional and subcellular distribution of ATP-citrate lyase and other enzymes of acetyl-CoA metabolism in rat brain. J Neurochem 35:775–785
4. Duelli R, Kuschinsky W (2001) Brain glucose transporters: relationship to local energy demand. News Physiol Sci 16:71–76
5. Roberts EL Jr (2007) The support of energy metabolism in the central nervous system with substrates other than glucose. In: Lajtha A, Gibson GE, Dienel GA (eds) Handbook of neurochemistry and molecular neurobiology. Brain energetics. Integration of molecular and cellular processes. Springer, Berlin, pp 139–179
6. Szutowicz A, Tomaszewicz M, Bielarczyk H (1996) Disturbances of acetyl-CoA, energy and acetylcholine metabolism in some encephalopathies. Acta Neurobiol Exp 56:323–339
7. Szutowicz A, Tomaszewicz M, Jankowska A, Kisielewski Y (1994) Acetylcholine synthesis in nerve terminals of diabetic rats. NeuroReport 5:2421–2424
8. Serres S, Raffard G, Franconi JM, Merle M (2008) Close coupling between astrocytic and neuronal metabolomics to fulfill anaerobic and energy needs in the rat brain. J Cereb Blood Flow Metab 28:712–724
9. Halestrap AP, Wilson MC (2012) The monocarboxylate transporter family—role and regulation. IUBMB Life 64:109–119
10. Wohlsnald S, Burgers HF, Kuschinsky W, Maurer MH (2010) Neurons and neuronal stem cells survive in glucose-free lactate and in high glucose cell culture medium during normoxia and anoxia. Neurochem Res 35:1635–1642
11. Diener GA (2011) Brain lactate metabolism: the discoveries and the controversies. J Cereb Blood Flow Metab 32:1107–1138
12. Baslow MH (2007) N-acetylaspartate and N-acetylaspartylglutamate. In: Oja SS, Schousboe A, Saransaari P (eds) Handbook of neurochemistry and molecular biology. Amino acids and peptides in the nervous system, 3rd edn. Springer, New York, pp 305–346
13. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57:695–703
14. Szutowicz A, Tomasewicz M, Bielarczyk H, Jankowska A (1998) Putative significance of shifts in acetyl-CoA compartmentalization in nerve terminals for disturbances of cholinergic transmission in brain. Devel Neurosci 20:485–492
15. Szutowicz A, Tomaszewicz M, Jankowska A, Madzjar B, Bielarczyk H (2000) Acetyl-CoA metabolism in cholinergic neurons and their susceptibility to neurotoxic inputs. Met Brain Dis 15:29–44
16. Bhatt DP, Houdek HM, Watt JA, Rosenberger TA (2013) Acetate supplementation increases brain phosphocreatine and reduces AMP levels with no effects on mitochondrial biogenesis. Neurochem Int 62:296–305
17. Soliman ML, Ping KL, Combs CK, Rosenberger TA (2012) Acetate reduces microglial inflammatory signaling in vitro. J Neurochem 123:555–567
18. Deelchand DK, Nelson C, Shestov AA, Ugurbil K, Henry PG (2009) Simultaneous measurement of neuronal and glial metabolism in rat brain in vivo using co-infusion of [1,6–13C]glucose and [1,2,13C]acetate. J Magn Reson 196:157–163
19. Laughton JD, Bittar P, Charnay Y, Pellerin L, Kovari E, Magistretti PJ, Bouras C (2007) Metabolic compartmentalization in the human cortex and hippocampus: evidence for a cell- and region-specific localization of lactate dehydrogenase 5 and pyruvate dehydrogenase. BMC Neurosci 8:35
20. Halim ND, McFate T, Mohyeldin A, Okagaki P, Korotchkin LG, Patel MS, Jeoung NH, Harris RA, Schell MJ, Verma A (2010) Phosphorylation status of pyruvate dehydrogenase distinguishes metabolic phenotypes of cultured rat brain astrocytes and neurons. Glia 58:1168–1176
21. Chandhi GK, Cruz NF, Ball KK, Dienel GA (2009) Astrocytes are poised for lactate trafficking and release from activated brain and for supply of glucose to neurons. J Neurochem 111:522–536
22. Pellerin L (2003) Lactate as a pivotal element in neuron-glia metabolite cooperation. Neurochem Int 43:331–338
23. Bergersen LH (2007) Is lactate food for neurons? Comparison of monocarboxylate transporter subtypes in brain and muscle. Neuroscience 145:11–19
24. Sonnewald U, Schousboe A, Qu H, Waagepetersen HS (2004) Intracellular metabolic compartmentation assessed by [13C] magnetic resonance spectroscopy. Neurochem Int 45:305–310
25. Leong SF, Lai JCK, Lim L, Clark JB (1981) Energy-metabolising enzymes in brain regions of adult and aging rats. J Neurochem 37:1548–1556
26. Szutowicz A, Jankowska A, Blusztajin JK, Tomasewicz M (1999) Acetylcholine and acetyl-CoA metabolism in differentiating SN56 septal cell line. J Neurosci Res 57:131–136
27. Szutowicz A, Bielarczyk H, Gul S, Ronowska A, Pawelczyk T, Jankowska-Kulawy A (2006) Phenotype-dependent susceptibility of cholinergic neuroblastoma cells to neurotoxic inputs. Metab Brain Dis 21:149–161
28. Cremer JE, Teal HM (1974) The activity of pyruvate dehydrogenase in rat brain during postnatal development. FEBS Lett 39:17–20
29. Malloch GDA, Munday LA, Olson MS, Clark JB (1986) Comparative development of the pyruvate dehydrogenase complex and citrate synthase in rat brain mitochondria. Biochem J 238:729–736
30. Buerstatte CR, Behar KL, Novotny EJ Jr, Lai JCK (2000) Brain regional development of the activity and α-ketoglutarate dehydrogenase complex in the rat. Devel Brain Res 125:139–145
31. Szutowicz A, Kabata J, Łysiak W (1980) ATP citrate lyase and other enzymes of acetyl-CoA metabolism in developing rat cerebrum and cerebellum. Int J Biochem 11:545–549
32. Albers DS, Beal MF (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neurol Transm [Suppl] 59:133–154
33. Di Domenico F, Perluigi M, Butterfield DA, Cornelius C, Uranga RM, Bruce-Keller AJ, Morrison CD, Fernandez-Kim J, 34. Bielarczyk H, Gul S, Ronowska A, Jankowska-Kulawy A, Bielarczyk H, Pawełczyk T, Szutowicz A, Łysiak W, Angielski S (1977) Effect of (−)-hydroxycitrate on pyruvate metabolism in rat brain synaptosomes. J Neurochem 24:851–58
34. Jankowska-Kulawy A, Bielarczyk H, Romianowski P, Pawełczyk T, Szutowicz A (2006) RS-lipoic amid protects mitochondria against the injury induced by hydroxycitrate. Biochem J 395:405–11
35. Schuberth J, Sollenberg J, Sundwall A, Sorbo B (1966) Acetylcoenzyme A and acetylcholine in brain. The effect of centrally active drugs, insulin coma and hypoxia. J Neurochem 16:819–822
36. Ronowska A, Bielarczyk H (1987) Elimination of CoA-SH interference from acetyl-CoA assay by maleic anhydride. Anal Biochem 164:292–296
37. Ronowska A, Bielarczyk H, Pawelczyk T, Tomaszewicz M, Bielarczyk H, Pawelczyk T, Wroblewska M, Szutowicz A (2010) Acetyl-CoA and acetylcholine metabolism in nerve terminal compartment of thiamine deficient rat brain. J Neurochem 115:333–342
38. Ronowska A, Gul-Hinc S, Bielarczyk H, Pawelczyk T, Szutowicz A (2007) Effects of zinc on SN56 cholinergic neuroblastoma cells. J Neurochem 103:972–983
39. Ronowska A, Dyś A, Jankowska-Kulawy A, Klimaszewska-Lata J, Bielarczyk H, Romaniowska P, Pawelczyk T, Szutowicz A (2010) Short-term effects of zinc on acetylcholine metabolism and viability of SN56 cholinergic neuroblastoma cells. Neurochem Int 56:143–151
40. Paradies G, Pertosillo G, Paradies V, Ruggiero FM (2011) Mitochondrial dysfunction in brain aging: role of oxidative stress and cardiolipin. Neurochem Int 58:447–457
41. Zhou Q, Lam PY, Han D, Cadenas E (2009) Activation of c-Jun-N-terminal kinase and decline of mitochondrial pyruvate dehydrogenase activity during brain aging. FEBS Lett 583:1132–1140
42. Gaynn RW, Gelberg JH, Veech R (1973) Equilibrium constants of the malate dehydrogenase, citrate synthase, citrate lyase, and acetyl-CoA hydroylation reactions under physiological conditions. J Biol Chem 248:6957–6965
43. Choi CH, Zimon A, Usheva A (2005) Metabolic stress regulates basic transcription through acetyl-coenzyme A. Cell Mol Life Sci 62:625–628
44. Ricny J, Tucek S (1980) Relation between the content of acetyl-coenzyme A and acetylcholine in brain slices. Biochem J 188:683–688
45. Ricny J, Tucek S (1980) Mitochondrial permeability transition pore modulates Ca²⁺ responses to physiological stimuli in adult neurons. Eur J Neurosci 33:831–842
46. Deutsch J, Rapoport SI, Rosenberger TA (2003) Valproyl-CoA and estrified valproic acid are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered. Neurochem Res 28:861–866
47. Kato T (1978) Ischemic effect on CoASH and acetyl-CoA concentration levels in cerebrum, cerebellum and liver of mice. J Neurochem 31:1545–1547
48. Reynolds SF, Blass JP (1975) Normal levels of acetyl coenzyme A and acetylcholine in the brains of thiamine deficient rats. J Neurochem 24:185–186
49. Ricny J, Tucek S (1981) Acetyl-coenzyme A and acetylcholine in slices of rat cudate nuclei incubated in the presence of metabolic inhibitors. J Biol Chem 256:4919–4923
50. Ricny J, Tucek S (1983) Ca²⁺ ions and the output of acetyl-CoA from brain mitochondria. Gen Physiol Biophys 2:27–37
51. Shea PA, Aprison MH (1977) The distribution of acetyl-CoA in specific areas of the CNS of the rat and measured by modification of a radio-enzymatic assay for acetylcholine and choline. J Neurochem 28:51–58
52. Chen H, Calabrese V (2010) Oxidative damage in rat brain during aging: interplay between energy and metabolic key target proteins. Neurochem Res 35:2184–2192
53. Cha J, Choe J, Kwon MJ, Park JH, Oh JY, Kim SH, Kim SH, Cho JS, Lee YT, Kim HS, Kim SH (2010) Dietary n-3 polyunsaturated fatty acids affect the expression of antioxidative enzymes in the rat brain. J Neurochem 114:344–361
54. Frank KA, Blankenship GS, Aoi O, Oishi I, Hirose Y, Kato K, Manji HK, Potenza MN (2011) Acetylcholine, but not dopamine, regulates PPARγ activity and synaptogenesis in cultured neurons. J Neurochem 119:104–118
55. Calabrese V (2010) Oxidative damage in rat brain during aging: interplay between energy and metabolic key target proteins. Neurochem Res 35:2184–2192
68. Hartikka J, Hefi F (1988) Development of septal cholinergic neurons in culture: plating density and glial cells modulate effects of NGF on survival, fiber growth, and expression of transmitter specific enzymes. J Neurosci 8:2967–2985
69. Auld DS, Menningen F, Quirion R (2001) Nerve growth factor rapidly induces prolonged acetylcholine release from cultured basal forebrain neurons: differentiation between neurromodulatory and neurotrophic influences. J Neurosci 21:3375–3382
70. Yamada T, Inazu M, Tajima H, Matsumiya T (2011) Functional expression of choline transporter-like protein 1 (CTL1) in human neuroblastoma cells and its link to acetylcholine synthesis. Neurochem Int 58:354–365
71. Efange SMN, Garland EM, Stanley JK, Khare AB, Mash DC (1997) Vesicular acetylcholine transporter density and Alzheimer’s disease. Neurobiol Aging 18:407–413
72. Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and Alzheimer’s disease. J Neural Transm 113:1625–1644
73. Vanucchi MG, Pepeu G (1987) Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats. Neurobiol Aging 8:403–407
74. Wang F, Chen H, Sun X (2009) Age-related spatial cognitive impairment is correlated with a decrease in ChAT in cerebral cortex, hippocampus and forebrain of SAMP8 mice. Neurosci Lett 454:212–217
75. Fortress AM, Buhusi M, Helke KL, Granholm ACE (2011) Cholinergic degeneration and alterations in the TrkA and p75NTR balance as a result of pro-NGF injection into aged rats. J Aging Res. doi: 10.4061/2011/460543
76. Richardson PJ (1981) Quantitation of cholinergic synaptosomes from guinea pig brain. J Neurochem 37:258–260
77. Bielarczyk H, Tomaszewicz M, Madziar B, ´wikowska J, Fortress AM, Buhusi M, Helke KL, Granholm ACE (2011) Functional expression of choline transporter-like protein 1 (CTL1) in human neuroblastoma cells and its link to acetylcholine synthesis. Neurochem Int 58:354–365
78. Lefresne P, Guyenet P, Glowinski J (1973) Acetylcholine synthesis from [2- 14C] pyruvate in rat striatal slices. J Neurochem 20:1083–1097
79. Bielarczyk H, Jankowska A, Madziar B, Matecki A, Michno A, Szutowicz A (2003) Differential toxicity of nitric oxide, aluminum and amyloid-beta peptide in SN56 cholinergic cells from mouse septum. Neurochem Int 42:323–331
80. Cai L, Sutter BM, Li B, Tu BP (2010) Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol Cell 42:426–437
81. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee VMY, Trojanowski JQ (2012) Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies. Brain 135:807–818
82. Szutowicz A, Srere PA, Allen CN, Crawford IL (1982) Effects of septal lesions on enzymes of acetyl-CoA metabolism in the cholinergic system of the rat hippocampus. J Neurochem 39:458–463
83. Szutowicz A, Morrison MR, Srere PA (1983) The enzymes of acetyl-CoA metabolism in differentiating cholinergic (S-20) and noncholinergic (NIE-1150 neuroblastoma) cells. J Neurochem 40:1664–1770
84. Selwyn MJ (1987) Holes in mitochondrial inner membranes. Nature 330:424–425
85. Ando S, Tadenuma T, Tanaka Y, Fukui F, Kobayashi S, Ohashi Y, Kawabata T (2001) Enhancement of learning capacity and cholinergic synaptic function by carnitine in aging rats. J Neurosci Res 66:266–271
86. Aureli T, Miccheli A, Ricciolini R, DiCocco ME, Ramacce MT, Agelucci L, Ghirardi O, Conti F (1990) Aging brain: effect of acetyl-L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 31P and 1H NMR spectroscopy. Brain Res 526:108–112
87. Smeland OB, Meisingset TW, Sonnewald U (2012) Dietary supplementation with acetyl-L-carnitine in seizure treatment of phenylenetetrazole kindled mice. Neurochem Int 61:444–454
88. Pettegrew JW, Klink WE, Pangchalingam K, Kanfer JM, McCle- lure RJ (1995) Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer’s disease. Neurobiol Aging 16:1–4
89. Crochemore C, Pena-Altamira E, Virgili M, Monti B, Contestabile A (2005) Disease-related regressive alterations of forebrain cholinergic system in SOD1 mutant transgenic mice. Neurochem Int 46:357–368
90. Fiskum G, Murphy AN, Beal FM (1999) Mitochondria in neurogenesis: acute ischemia an chronic neurodegenerative deaseases. J Cereb Blood Flow Metab 19:351–369
91. Martin LJ (2010) Mitochondrial pathobiology in Parkinson’s disease and amyotrophic lateral sclerosis. J Alzheimer’s Dis 20:S335–S356
92. Pappas BA, Bayley PJ, Bui BK, Hansen LA, Thal LJ (2000) Choline acetyltransferase activity and cognitive domain scores of Alzheimer’s patients. Neurobiol Aging 21:11–17
93. Higgins GC, Beart PM, Shin YS, Chen MJ, Cheung NS, Nagley P (2010) Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. J Alzheimer’s Dis 20(Suppl 2):S255–S263
94. Sun J, Feng X, Liang D, Duan Y, Lei H (2012) Down-regulation of energy metabolism in Alzheimer’s disease is a protective response of neurons to the microenvironment. J Alzheimer’s Dis 28:389–402
95. Hoyer S, Follich I (2007) Dementia: the significance of cerebral metabolic disturbances in Alzheimer’s disease. Relation to Parkinson’s disease. In: Lajtha A, Moussa BH, Riederer P, Mandel SA, Battistin L (eds) Handbook of neurochemistry and molecular biology 3rd edition, degenerative diseases of the nervous system. Springer, New York, pp 189–232
96. Selkoe DJ (1994) Alzheimer’s disease: a central role of amyloid. Annu Rev Neurosci 17:481–513
97. Walsh DM, Selkoe DJ (2007) Aβ oligomers—a decade of discovery. J Neurochem 101:1172–1184
98. Xu PT, Li YJ, Qin XJ, Scherer CR, Xu H, Schmechel DE, Hulette CM, Ervin J, Gullans SR, Haines J, Peicak-Vance MA, Gilbert JR (2006) Differences in apolipoprotein E3 and E4 allele-specific gene expression in hippocampus in Alzheimer’s disease. Neurobiol Dis 21:256–275
99. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature Gen 39:17–23
100. Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M, Chen G (2012) Impaired mitochondrial function in psychiatric disorders. Nature Rev Neurosci 13:293–307
101. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature Gen 39:17–23
102. Chen HK, Ji YS, Dodson SE, Miranda RD, Rosenblum CL, Reynolds JJ, Freedman SB, Weisgraber KH, Huang Z, Mahlezw R (2011) Apolipoprotein E4 domain interaction, mediates detri- mental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem 286:5215–5221
103. Gibson GE, Haroutunian V, Zang H, Park LCH, Shi Q, Lesser M, Moos RC, Sheu RKF, Blass JP (2000) Mitochondrial damage in Alzheimer’s disease varies with apolipoprotein E genotype. Ann Neurol 48:297–303
105. Terwel D, Bothmer J, Wolf E, Meng F, Jolles J (1998) Affected enzyme activities in Alzheimer’s disease are sensitive to antemortem hypoxia. J Neurol Sci 161:47–56

106. Benson DF (1983) Alterations in glucose metabolism in Alzheimer’s disease. Banbury report 15. Cold Spring Harbor Laboratory, pp 309–315

107. Kalaria RN, Harik SI (1989) Reduced glucose transporter at blood-brain barrier and in cerebral cortex in Alzheimer’s disease. J Neurochem 53:1083–1088

108. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL (1995) Neurochemical correlates of dementia severity in Alzheimer’s disease: relative importance of cholinergic deficits. J Neurochem 64:749–760

109. Armstrong DM, Sheffield R, Mishizen-Eberz AJ, Carter TL, Rissman RA, Mizukami K, Ikonomidou MD (2003) Plasticity of glutamate and GABA_A receptors in the hippocampus of patients with Alzheimer’s disease. Cell Mol Neurobiol 23:491–505

110. Lyness SA, Zarow C, Chui HC (2003) Neuron loss in key cholinergic and amineergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 24:1–23

111. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137–147

112. Kar S, Slowikowski S, Westady D, Mount HTJ (2004) Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease. J Psychiatry Neurosci 29:427–441

113. Moncada S, Bolanos JP (2006) Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 97:1676–1689

114. Murphy MP, LeVine H III (2010) Alzheimer’s disease and amyloid-β peptide. J Alzheimer’s Dis 19:311–323

115. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137–147

116. Szutowicz A (2001) Aluminum, NO, and nerve growth factor signaling in brain function, dysfunction, and dementia. Neurosci Biobehav Rev 25:999–1018

117. Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sartorio MA, Terstappen GC, Nicoletti F (2003) The Wnt pathway, cell-cycle activation and β-amyloid: novel therapeutic strategies in Alzheimer’s disease? Trends Pharmacol Sci 24:233–238

118. Perez SE, He B, Muhmmad N, Oh KJ, Fahnestock M, Ikonomidou MD, Mufson EJ (2011) Cholinotropic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiol Dis 41:338–352

119. Oh JD, Chartisathan K, Chase TN, Butcher LL (2000) Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrain. Brain Res 853:174–185

120. Takeda A (2011) Zinc signaling in the hippocampus and its relation to pathogenesis of depression. Mol Neurobiol 44:166–174

121. Frederickson CJ, Maret W, Cuajungco MP (2004) Zinc and excitotoxic brain injury. Neuroscientist 10:16–25

122. Mocchegiani E, Bertoni-Freddari C, Marcellini F, Malavolta M (2005) Brain, aging and neurodegeneration: role of zinc ion availability. Progr Neurobiol 75:367–390

123. Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer’s disease. Neurochem Int 45:583–595

124. Supnet C, Bezprozvanny I (2010) Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer’s disease. J Alzheimer’s Dis 20:S487–S498

125. Yu JT, Chang RCC, Tan L (2009) Calcium dysregulation in Alzheimer’s disease: from mechanisms to therapeutic opportunities. Progr Neurobiol 89:240–255

126. Berridge MJ (2011) Calcium signaling and Alzheimer’s disease. Annu Rev Physiol 73:284–307

127. Zaidi R, vårholme E, Muzio M, Marzo I, Varki A, Lee VM, Kleeberger SR (2010) Neurons in the olfactory bulb are affected in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 81:1266–1268

128. Lai CK, DiLorenzo JC, Sheu KFR (1988) Pyruvate dehydrogenase is inhibited in calcium-loaded cerebral cortical mitochondria. Neurochem Res 13:1043–1048

129. Zatta P, Lucchini R, Rensburg SJ, Taylor A (2003) The role of metals in neurodegenerative processes: aluminum, manganese and zinc. Brain Res Bull 62:15–28

130. Bizon-Zygmańska D, Jankowska-Kulawy A, Bielarczyk H, Pawełczyk T, Ronowska A, Marszall M, Szutowicz A (2011) Acetyl-CoA metabolism in amyloid-ε4-evoked thiamine pyrophosphate deficiencies in cholinergic SN56 neuroblastoma cells. Neurobiol Aging 32:S20–S36

131. Bossy-Wetzel E, Talantova MV, Lee WD, Scholzke MN, Harrop A, Mathews E, Gotz T, Han J, Ellisman MH, Perkins GA, Lipton SA (2004) Crosstalk between nitric oxide and zinc pathways to neuronal cell death involving mitochondrial dysfunction and p38-activated K⁺ channels. Neuron 41:351–365

132. Doherty GH (2011) Nitric oxide in neurodegeneration: potential benefits of non-steroidal anti-inflammatory agents. Neurosi Bull 27:366–382

133. Personett DA, Williams K, Baskerville KA, McKinney M (2007) Establishment of cholinergic neuron-like cell lines with differential vulnerability to nitrosative stress. Curr Neurovasc Res 4:75–88

134. Fass U, Panickar K, Personett D, Bryant D, Williams K, Gonzalez J, Sugaya K, McKinney M (2000) Differential vulnerability of primary cultured cholinergic neurons to nitric oxide excess. NeuroReport 11:931–936

135. McKinney M, Williams K, Personett D, Kent C, Bryant D, Gonzalez J, Baskerville K (2004) Ponceine cholinergic neurons depend on three neuroprotection systems to resist nitrosative stress. Brain Res 1002:100–109

136. Personett D, Fass U, Panickar K, McKinney M (2000) Retinoic acid-mediated enhancement of the cholinergic/neuronal nitric oxide synthase phenotype of the medial septal SN56 clone establishment of nitric oxide-sensitive proapoptotic state. J Neurochem 74:2412–2424

137. Benilova I, Karran E, De Strooper B (2012) The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nature Rev Neurol 7:284–294

138. Butterworth RF (2003) Thiamin deficiency and brain disorders. Nutr Res Rev 16:277–283

139. Zahr NM, Kimberley L, Harper K, Harper CG (2011) Clinical symptoms and diagnostic approaches in the predisposition to Alzheimer’s disease. Curr Opin Neurol 24:233–238

140. Zauderer RB, Mcquade TT, Mcquade DD, Piccione M, Delaney J, Reynolds K (2011) The role of the thalamic dopaminergic innervation in the pathogenesis of depression. Mol Neurobiol 44:342–355

141. Klunk WE (2011) Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 32:S20–S36
145. Robakis NK (2011) Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives. Neurobiol Aging 32:372–379

146. Ishii K, Tamaoka A, Mizusawa H, Shoji SI, Ohtake T, Fraser PE, Takahashi H, Tsu S, Gearing M, Mizutani T, Yamada S et al (1997) Aβ1-40 but not Aβ1-42 levels in cortex correlate with apolipoprotein E ε4 allele dosage in sporadic Alzheimer’s disease. Brain Res 748:250–252

147. Nashlund J, Haroutunian V, Mohs R, Davis KI, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 283:1571–1577

148. Hoshi M, Takahashi A, Yasutake K, Yoshida N, Ishiguro K, Hoshino T, Imahori K (1997) Non-toxic amyloid β peptide 1–42 suppresses acetylcholine synthesis. J Biol Chem 272:2038–2041

149. Perreira C, Santos MS, Oliveira C (1999) Involvement of oxidative stress on the impairment of energy metabolism induced by Aβ peptides on PC12 cells: protection by antioxidants. Neurobiol Dis 6:209–219

150. Keller JN, Pang Z, Geddes JW, Germeyer A, Waeg G, Mattson MPJ (1997) Impairment of glucose and glutamate transport and induction mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid-beta peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 69:273–279

151. Olsen OF, Dago L, Mikkelsen JD (1998) Amyloid β neurotoxicity in the cholinergic but not in the serotoninergic phenotype of RN46A cells. Mol Brain Res 57:266–274

152. Resende R, Pereira C, Agostinho P, Vieira AP, Malva JO, Oliveira CR (2007) Susceptibility of hippocampal neurons to Aβ peptide toxicity is associated with perturbation in Ca2+ homeostasis. Brain Res 1143:11–21

153. Harkany TO, Mahony S, Keikser J, Kelly JP, Konya C, Borostyankoi ZA, Gorcs TJ, Zarandi M, Penke B, Leonard BE, Luiten PGM (2001) β-Amyloid (1–42)-induced cholinergic lesions in rat nucleus basalis bidirectionally modulate serotonergic innervation of the basal forebrain and cerebral cortex. Neurobiol Dis 8:587–667

154. Sarkar P, Narayanan J, Harder DR (2011) Differential effect of amyloid beta on the cytochrome P450 epoxygenase activity in rat brain. Neuroscience 194:241–249

155. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS (2004) Amyloid-β-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and the cell-dependent kinase 5 expression. J Neurochem 88:554–563

156. Karuppagounder SS, Xu H, Shi Q, Chen LH, Pechners K, Kopitz J, Siegelin M, Schliebs R (2010) Insulin-like growth factor-1 receptor and cognitive decline in the Tg2576 transgenic mouse model of Alzheimer’s disease. Brain Res 1249:222–228

157. Hellstrom-Lindahl E, Viitanen M, Marutle A (2009) Comparison of Aβ levels in the brain of familial and sporadic Alzheimer’s disease. Neurochem Int 55:243–252

158. Liu L, Ikonen S, Heikkinen T, Tapiola T, VanGroen T, Tanila H (2002) The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice. Exp Neurol 173:196–204

159. Testa M, Fila T, Barabas P, Contestabile A, Ciani E (2006) Choline acetyltransferase transferase in brain of Ts65Dn mice, an animal model for Down’s syndrome and related neurodegenerative diseases. J Neurochem 97:515–526

160. Ikarashi Y, Hatigaya Y, Tomidokoro Y, Kanai M, Ikeda M, Matsubara E, Kawaguchi K, Kuribara M, Younkin SG, Maruyama Y, Shoi M (2004) Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer’s disease. Brain Res 1249:222–228

161. Crawford JR, Bjorklund NL, Taglialetella G, Gomer RH (2012) Brain serum amyloid P levels are reduced in individuals that lack dementia while having Alzheimer’s disease neuropathology. Neurochem Res 37:795–801

162. Blanchard J, Wanka L, Tung YC, Cardenas-Aguayo MC, LaFerla FM, Iqbal K, Grunde-Iqbal I (2010) Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice. Acta Neuropathol 120:605–621

163. Hamilton LR, Aumont A, Julien C, Vadnais A, Calon F, Fernandez KJL (2010) Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of Alzheimer’s disease. Eur J Neurosci 32:905–920

164. Chapman PE, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Izirrany M, Younkin L, Good MA, Bliss TVP, Hyman BT, Younkin SG, Hsiao KK (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2:271–276

165. Buxbaum JD (2000) Correlation between elevated levels of Aβ1-42 and 3xTg-AD mice. Acta Neuropathol 120:605–621

166. Hamilton LR, Aumont A, Julien C, Vadnais A, Calon F, Fernandez KJL (2010) Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg-AD mice. Acta Neuropathol 120:605–621

167. Harkany TO, Mahony S, Keikser J, Kelly JP, Konya C, Borostyankoi ZA, Gorcs TJ, Zarandi M, Penke B, Leonard BE, Luiten PGM (2001) β-Amyloid (1–42)-induced cholinergic lesions in rat nucleus basalis bidirectionally modulate serotonergic innervation of the basal forebrain and cerebral cortex. Neurobiol Dis 8:587–667

168. Hellstrom-Lindahl E, Viitanen M, Marutle A (2009) Comparison of Aβ levels in the brain of familial and sporadic Alzheimer’s disease. Neurochem Int 55:243–252

169. Liu L, Ikonen S, Heikkinen T, Tapiola T, VanGroen T, Tanila H (2002) The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice. Exp Neurol 173:196–204

170. Testa M, Fila T, Barabas P, Contestabile A, Ciani E (2006) Choline acetyltransferase transferase in brain of Ts65Dn mice, an animal model for Down’s syndrome and related neurodegenerative diseases. J Neurochem 97:515–526

171. Ikarashi Y, Hatigaya Y, Tomidokoro Y, Kanai M, Ikeda M, Matsubara E, Kawaguchi K, Kuribara M, Younkin SG, Maruyama Y, Shoi M (2004) Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer’s disease. Brain Res 1249:222–228

172. Hellstrom-Lindahl E, Viitanen M, Marutle A (2009) Comparison of Aβ levels in the brain of familial and sporadic Alzheimer’s disease. Neurochem Int 55:243–252

173. Hamilton LR, Aumont A, Julien C, Vadnais A, Calon F, Fernandez KJL (2010) Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg-AD mice. Acta Neuropathol 120:605–621

174. Zhang Q, Yang G, Li W, Fa Z, Sun A, Luo J, Ke ZJ (2011) Aβ-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology 77:951–958

175. Crawford JR, Bjorklund NL, Taglialetella G, Gomer RH (2012) Brain serum amyloid P levels are reduced in individuals that lack dementia while having Alzheimer’s disease neuropathology. Neurochem Res 37:795–801

176. Blanchard J, Wanka L, Tung YC, Cardenas-Aguayo MC, LaFerla FM, Iqbal K, Grunde-Iqbal I (2010) Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice. Acta Neuropathol 120:605–621

177. Hamilton LR, Aumont A, Julien C, Vadnais A, Calon F, Fernandez KJL (2010) Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg-AD mice. Acta Neuropathol 120:605–621

178. Hamilton LR, Aumont A, Julien C, Vadnais A, Calon F, Fernandez KJL (2010) Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg-AD mice. Acta Neuropathol 120:605–621

179. Hamilton LR, Aumont A, Julien C, Vadnais A, Calon F, Fernandez KJL (2010) Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg-AD mice. Acta Neuropathol 120:605–621

180. Hamilton LR, Aumont A, Julien C, Vadnais A, Calon F, Fernandez KJL (2010) Widespread deficits in adult neurogenesis precede plaque and tangle formation in the 3xTg-AD mice. Acta Neuropathol 120:605–621
177. Bubber P, Zj Ke, Gibson GE (2004) Tricarboxylic acid cycle enzymes following thiamine deficiency. Neurochem Int 45: 1021–1028
178. Zhao N, Zhong C, Wang Y, Zhao Y, Gong N, Zhou G, Xu T, Hong Z (2008) Impaired hippocampal neurogenesis is involved in cognitive dysfunction induced by thiamine deficiency at early pre-pathological lesion stage. Neurobiol Dis 29:176–185
179. Plaitakis A, Hwang EC, Van Woert MH, Szilagyi PI, Berl S (1982) Effect of thiamin deficiency on brain neurotransmitter systems. Ann NY Acad Sci 378:367–381
180. Allen DD, Smith QR (1999) Blood-brain barrier choline transport in the senescent rat. Neurosci Lett 277:198–202
181. Wurtman RJ (1992) Choline metabolism as a basis for selective vulnerability of cholinergic neurons. TINS 15:117–122
182. Yamamura HI, Snyder SH (1973) High affinity transport of choline into synaptosomes of rat brain. J Neurochem 21: 1355–1374
183. Brock M, Nickel AC, Madziar B, Blusztajn JK, Berse B (2007) Differential regulation of the high affinity choline transporter and cholinergic locus by cAMP signaling pathways. Brain Res 1145:1–10
184. Blusztajn JK (1998) Choline, a vital amine. Science 281: 794–795
185. Glenn MJ, Kirby ED, Gibson EM, Wong-Goodrich SJ, Mellot TJ, Blusztajn JK, Williams CL (2008) Age-related declines in exploratory behavior and markers of hippocampal plasticity are attenuated by prenatal choline supplementation in rats. Brain Res 1237:110–123
186. Liapi C, Kyriakaki A, Zarros A, Al-Humadi H, Stolakis V, Gkrouzman E, Anifantaki F, Skandali N, Margaritis M, Tsakiris S (2009) Effect of adult-onset choline deprivation on the activities of acetylcholinesterase (Na+, K+)- and Mg2+ATPase in crucial rat brain regions. Food Chem Toxicol 47:82
187. Pacelli C, Coluccia A, Grattagliano I, Cocco T, Petrosillo G, Paradies G, De Nitto E, Massaro A, Persichella M, Borraci P, Portincasa P, Carratu MR (2010) Dietary choline deprivation impairs rat brain mitochondrial function and behavioral phenotype. J Nutr 40:1072–1079
188. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA 106:14670–14675